Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KIT Y553C |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| KIT Y553C | Advanced Solid Tumor | predicted - sensitive | Imatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gleevec (imatinib) treatment inhibited Kit autophosphorylation and viability of cells expressing KIT Y552C (corresponding to Y553C in human) in culture (PMID: 22083669). | 22083669 | |
| KIT Y553C | Advanced Solid Tumor | predicted - sensitive | Nilotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tasigna (nilotinib) treatment inhibited Kit autophosphorylation and viability of cells expressing KIT Y552C (corresponding to Y553C in human) in culture (PMID: 22083669). | 22083669 |